|

Standard of Care (SoC) Clinical Trials

4 actively recruiting trials across 4 locations

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Novartis Pharmaceuticals1
  • New Horizon Medical Solutions1
  • Merck Sharp & Dohme LLC1
  • Cellvax Therapeutics Inc1

Indications

  • Cancer3
  • Diabetic Foot Ulcer (DFU)1
  • Progressive Metastatic Castrate Resistant Prostate Cancer1
  • Prostate Cancer Patients Undergoing Radical Prostatectomy1
  • Prostate Cancers1

Tucson, Arizona1 trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Arizona Cancer Center at UMC North ( Site 0018)

Phase 3

Denver, Colorado1 trial

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Sarah Cannon Research Institute

Phase 1/2

Chicago, Illinois1 trial

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic

Phase 2

Dallas, Texas1 trial

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

Richard C. Galperin

N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.